TEThomas Ernandez

Thomas Ernandez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas Ernandez has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    New insights into the management of secondary hyperparathyroidism in non-dialysis dependent chronic kidney disease: extended release calcifediol

    by Spiros Arampatzis, Thomas Ernandez, Daniel Teta, Marco Bonani, Argyrios Georgalis, Stefan Flury, Antonio Bellasi

    This article examines the management of secondary hyperparathyroidism in non-dialysis dependent chronic kidney disease (NDD-CKD) patients in Switzerland, with a focus on optimizing bone and mineral health in CKD stages 3–4. The impact of vitamin D insufficiency on secondary hyperparathyroidism is discussed and current treatment options and challenges are explored. To support clinical practice, current secondary hyperparathyroidism management was analyzed, emphasizing monitoring practices for bone and mineral parameters alongside guidelines for prescribing vitamin D-based therapies. A treatment algorithm incorporating extended-release calcifediol, as well as insights from KDIGO (Kidney Disease: Improving Global Outcomes) for Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), are presented to refine therapeutic approaches. Key findings illustrate the absence of definitive clinical endpoints, leading to the proposed use of a 25(OH)D threshold <30 ng/mL (<75 nmol/L) to guide treatment initiation. Target 25(OH)D concentrations between 30–100 ng/mL (75–250 nmol/L) are advocated, with the 30 ng/mL level serving as a practical reference for CKD patients, consistent with KDIGO recommendations. While extended-release calcifediol has demonstrated biochemical efficacy in raising 25(OH)D and reducing parathyroid hormone levels, high-dose cholecalciferol has also shown efficacy, though data remain heterogeneous. These insights address the clinical relevance and provide actionable guidance for achieving and maintaining adequate vitamin D levels through the administration of extended-release calcifediol. This review underscores the importance of structured monitoring, evidence-based therapy initiation, and individualized care to improve bone and mineral metabolism in NDD-CKD patients, contributing to better long-term outcomes in this population.


  • Open Access

    Long-term citrate treatment in high-risk kidney stone formers is not associated with metabolic adverse effects

    by Alexander Ritter, Lea Bührer, Daniel G Fuster, Nasser A Dhayat, Olivier Bonny, Gregoire Wuerzner, Thomas Ernandez, Florian Buchkremer, Stephan Segerer, Laura Keller, et al.

    Background: Citrate is frequently applied in kidney stone formers (KSFs), yet long-term safety data are lacking. We evaluated the effects of prolonged citrate therapy on metabolic health, urinary risk factors and stone recurrence in high-risk KSFs in Switzerland. Methods: The Swiss Kidney Stone Cohort (SKSC) is a multicenter study including KSFs and controls. Blood and urine analyses were performed at baseline and longitudinally over 2 years in KSFs, with subsequent telephone follow-up for stone events. A total of 654 KSFs (110 with citrate, 544 without) and 207 controls were included. Outcomes comprised anthropometric indices (body mass index, body roundness index, waist-to-hip ratio), metabolic parameters, urinary relative supersaturation ratios (RSR), stone recurrence and stone composition. Results: No evidence for between-group differences in 1- to 2-year changes in anthropometric, glucose or lipid outcomes was identified. Anthropometric indices remained stable in both groups. HbA1c rose in non-citrate (NC) but not in citrate (C) group patients. High-density lipoprotein (HDL) cholesterol increased in both groups, while low-density lipoprotein (LDL) decreased only in C patients. Propensity score–matched analyses showed no between-group differences in 1- to 2-year changes in anthropometric, glucose or lipid outcomes, with only modest within-group changes in the C group (hemoglobin A1c, HDL- and LDL-cholesterol). Urine analyses showed a greater reduction in RSR for brushite among NC patients, whereas C patients had a stronger decline in uric acid (UA) RSR. Calcium oxalate RSR decreased similarly across groups. Stone recurrence was more frequent in C patients, with 43% versus 30% of NC patients changing stone type during follow-up. No shift toward calcium phosphate stones was observed in citrate users. Conclusions: Long-term citrate therapy appeared metabolically safe, and selectively reduced UA supersaturation, while non-treated patients showed a more pronounced decrease for brushite. Higher recurrence among treated patients may reflect different baseline risk. A prospective trial is warranted to clarify additive benefits of citrate beyond dietary-guided counseling.

  • Open Access

    Estimating 24-hour urine phosphate excretion from spot urine

    by Yongchao Li, Daniel G Fuster, Nasser A Dhayat, Harald Seeger, Alexander Ritter, Olivier Bonny, Gregoire Wuerzner, Thomas Ernandez, Stephan Segerer, Beat Roth, et al.

    Background: 24-hour urinary phosphate excretion (24hUrP) is indicative of intestinal phosphate absorption in steady-state conditions. Nevertheless, 24-hour urine collections are cumbersome and error-prone. Previous studies suggested that spot urine phosphate (uPi) could serve as a practical substitute to predict 24hUrP, however, these data originated only from patients with chronic kidney disease. Here, we investigated the validity of predictive equations using spot urine parameters to assess 24hUrP in a cohort with normal kidney function (eGFR >60 ml/min per 1.73 m2) including 761 kidney stone patients and 207 non-kidney stone formers as assessed by low-dose CT scans, the Swiss Kidney Stone Cohort (SKSC). Methods: Published equations for 24hUrP were tested in our cohort and a novel predictive equation was developed. Pearson correlation coefficients and Bland–Altman plots were used to assess the relationship between spot uPi and spot urine creatinine (uCr) and 24hUrP. Additionally, forward multivariate analysis was performed to predict uPi excretion. Results: Previously published equations provided less accurate prediction of 24hUrP from spot urine. Log-transformed 24hUrP with log-transformed spot uPi and creatinine yielded the best model fit. In addition, inclusion of age, sex, and BMI significantly improved prediction of 24hUrP. Compared with spot uPi and uCr alone (r2 = 0.0561, P < .001) the new equation predicted 24hUrP (r2 = 0.1820, P < .001) more accurately. Conclusions: Here, we present a new equation for predicting 24hUrP from spot urine samples of individuals with normal kidney function. This model has a moderate ability to explain 24hUrP variance but has the strength to use only parameters routinely collected in clinical settings such as spot urinary phosphate and creatinine, sex, BMI, and age.


  • Open Access

    Hydrochlorothiazide and Bone Mineral Density in Patients with Kidney Stones

    by Andreas Christe, Elias Primetis, Grazia M. Cereghetti, Dionysios Drakopoulos, Nasser A. Dhayat, Olivier Bonny, Alexander Ritter, Nilufar Mohebbi, Nicolas Faller, Lisa Pellegrini, et al.

    Key Points: Loss of bone mineral density at 3 years was similar in patients with calcium kidney stones randomized to hydrochlorothiazide or placebo. There was no association between hydrochlorothiazide dose and change in bone mineral density at 3 years. Results were consistent across sensitivity and per-protocol analyses. Background: Low bone mass and fractures are common among kidney stone formers, yet it remains unclear whether thiazides can help preserve bone mass. We aimed to evaluate the effectiveness of a range of hydrochlorothiazide (HCTZ) doses compared with a placebo on bone mineral density (BMD) over a 3-year period. Methods: This post hoc analysis was conducted on data from the NOSTONE trial, a multicenter, randomized, controlled study. A total of 416 adults with recurrent calcium stones participated in the study, receiving either placebo or HCTZ at doses of 12.5, 25, or 50 mg daily. BMD was measured using computed tomography at the T12–L3 vertebrae at both baseline and the end of the study. Results: Over a median follow-up period of 2.92 years, the mean BMD decreased by 6.4±15.7 Hounsfield units (HU) in the placebo group, 5.1±15.1 HU in the 12.5 mg HCTZ group (β coefficient versus placebo, 0.37 HU; 95% confidence interval [CI], −1.74 to 2.47; P = 0.73), 4.1±16.3 HU in the 25 mg HCTZ group (β, 0.93 HU; 95% CI, −1.34 to 3.19; P = 0.42), and 4.8±15.9 HU in the 50 mg HCTZ group (β, 0.70 HU; 95% CI, −1.45 to 2.85; P = 0.52). No association was observed between HCTZ dose and BMD at the end of the study (P = 0.43). The results were confirmed in sensitivity analyses for eGFR, urine calcium, net gastrointestinal alkali absorption, and body mass index; in subgroup; and in per-protocol analyses. Conclusions: In patients with recurrent calcium kidney stones, loss of BMD was similar in patients receiving HCTZ at a dose of 12.5, 25, or 50 mg or placebo once daily. Clinical Trial registry name and registration number: NCT03057431.


  • Open Access

    Acid excretion is impaired in calcium oxalate stone formers

    by Pedro H Imenez Silva, Nasser A Dhayat, Daniel G Fuster, Harald Seeger, Alexander Ritter, Thomas Ernandez, Florian Buchkremer, Beat Roth, Olivier Bonny, Isabel Rubio-Aliaga, et al.


  • Open Access

    The Swiss Kidney Stone Cohort: A Longitudinal, Multicentric, Observational Cohort to Study Course and Causes of Kidney Stone Disease in Switzerland

    by Olivier Bonny, Daniel Fuster, Harald Seeger, Thomas Ernandez, Florian Buchkremer, Gregoire Wuerzner, Nasser Dhayat, Alexander Ritter, Catherine Stoermann, Stephan Segerer, et al.

    Background: Kidney stone disease has a high prevalence worldwide of approximately 10% of the population and is characterized by a high recurrence rate. Kidney stone disease results from a combination of genetic, environmental, and lifestyle risk factors, and the dissection of these factors is complex. Methods: The Swiss Kidney Stone Cohort (SKSC) is an investigator-initiated prospective, multicentric longitudinal, observational study in patients with kidney stones followed with regular visits over a period of 3 years after inclusion. Ongoing follow-ups by biannual telephone interviews will provide long-term outcome data. SKSC comprises 782 adult patients (age >18 years) with either recurrent stones or a single stone event with at least one risk factor for recurrence. In addition, a control cohort of 207 individuals without kidney stone history and absence of kidney stones on a low-dose CT scan at enrolment has also been recruited. SKSC includes extensive collections of clinical data, biochemical data in blood and 24-h urine samples, and genetic data. Biosamples are stored at a dedicated biobank. Information on diet and dietary habits was collected through food frequency questionnaires and standardized recall interviews by trained dieticians with the Globodiet software. Conclusion: SKSC provides a unique opportunity and resource to further study cause and course of kidney disease in a large population with data and samples collected of a homogeneous collective of patients throughout the whole Swiss population.